| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8773580 | Kidney International | 2006 | 6 Pages |
Abstract
The treatment of primary glomerular diseases has previously focused on relatively toxic immunosuppressive regimens. We are now seeing a paradigm shift from these toxic 'nonspecific' therapies to selective immunomodulating and immunosuppressive regimens. In this article, the experience with these newer agents including mycophenolate, rituximab, sirolimus, calcineurin inhibitors, and eculizumab are described.
Related Topics
Health Sciences
Medicine and Dentistry
Nephrology
Authors
G.B. Appel, M. Waldman, J. Radhakrishnan,